• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

重组组织型纤溶酶原激活剂治疗犬栓塞性肺动脉高压。推注与短期给药对溶栓动力学及肺血管压力-血流特性的影响。

Recombinant tissue-type plasminogen activator in canine embolic pulmonary hypertension. Effects of bolus versus short-term administration on dynamics of thrombolysis and on pulmonary vascular pressure-flow characteristics.

作者信息

Prewitt R M, Shiffman F, Greenberg D, Cook R, Ducas J

机构信息

Department of Medicine, University of Manitoba, Winnipeg, Canada.

出版信息

Circulation. 1989 Apr;79(4):929-38. doi: 10.1161/01.cir.79.4.929.

DOI:10.1161/01.cir.79.4.929
PMID:2494007
Abstract

We used a canine model of embolic pulmonary hypertension, induced by injection of autologous radioactive blood clots, to investigate effects of recombinant tissue-type plasminogen activator (rt-PA) on dynamics of thrombolysis and on pulmonary pressure-flow (PQ) characteristics. Over 5 (rt-PA5) or 15 (rt-PA15) minutes, 1 mg/kg rt-PA was infused. Rate and extent of thrombolysis were assessed by counting over both lung fields with a gamma camera. Emboli increased mean pulmonary artery pressure from 14 to 36 mm Hg (p less than 0.005). This change was predominantly due to an increase in the effective outflow pressure (PI) (from 9 to 29 mm Hg, p less than 0.001), obtained by extrapolation from the linear PQ relation. While pulmonary hemodynamics improved with rt-PA5 and rt-PA15, the change was greatest with rt-PA15. For example, the increase in PI that occurred with embolization was abolished with rt-PA15. Also, the decrease in pulmonary artery pressure was greatest with rt-PA15. While not significantly different, extent of total clot lysis tended to be greatest with rt-PA15 (p less than 0.07). Also, while during infusion, the concentration of rt-PA5 was threefold that of rt-PA15, the corresponding rate of thrombolysis was similar with rt-PA5 and rt-PA15. These results indicate that the improvement in pulmonary hemodynamics with rt-PA is primarily explained by a decrease in PI. Furthermore, they suggest an upper limit to the dose-thrombolytic rate relation with rt-PA.

摘要

我们使用了一种由注射自体放射性血凝块诱导的栓塞性肺动脉高压犬模型,来研究重组组织型纤溶酶原激活剂(rt-PA)对溶栓动力学和肺压力-血流(PQ)特征的影响。在5分钟(rt-PA5组)或15分钟(rt-PA15组)内,输注1mg/kg的rt-PA。通过γ相机对双侧肺野计数来评估溶栓的速率和程度。栓塞使平均肺动脉压从14mmHg升高至36mmHg(p<0.005)。这种变化主要是由于有效流出压(PI)升高(从9mmHg升至29mmHg,p<0.001),该值通过从线性PQ关系外推获得。虽然rt-PA5组和rt-PA15组的肺血流动力学均有改善,但rt-PA15组的变化最大。例如,rt-PA15组消除了栓塞时发生的PI升高。此外,rt-PA15组肺动脉压的降低幅度最大。虽然差异不显著,但rt-PA15组的总凝块溶解程度趋于最大(p<0.07)。而且,在输注过程中,rt-PA5组的rt-PA浓度是rt-PA15组的三倍,但rt-PA5组和rt-PA15组相应的溶栓速率相似。这些结果表明,rt-PA改善肺血流动力学主要是由于PI降低。此外,它们提示了rt-PA剂量-溶栓速率关系的上限。

相似文献

1
Recombinant tissue-type plasminogen activator in canine embolic pulmonary hypertension. Effects of bolus versus short-term administration on dynamics of thrombolysis and on pulmonary vascular pressure-flow characteristics.重组组织型纤溶酶原激活剂治疗犬栓塞性肺动脉高压。推注与短期给药对溶栓动力学及肺血管压力-血流特性的影响。
Circulation. 1989 Apr;79(4):929-38. doi: 10.1161/01.cir.79.4.929.
2
Treatment of canine embolic pulmonary hypertension with recombinant tissue plasminogen activator. Efficacy of dosing regimes.用重组组织型纤溶酶原激活剂治疗犬栓塞性肺动脉高压。给药方案的疗效。
Circulation. 1988 Jul;78(1):214-20. doi: 10.1161/01.cir.78.1.214.
3
Thrombolytic therapy in canine pulmonary embolism. Comparative effects of urokinase and recombinant tissue plasminogen activator.犬肺栓塞的溶栓治疗。尿激酶和重组组织型纤溶酶原激活剂的比较效果。
Am Rev Respir Dis. 1990 Feb;141(2):290-5. doi: 10.1164/ajrccm/141.2.290.
4
Rapid reversal of canine thromboembolic pulmonary hypertension by bolus injection of the novel recombinant plasminogen activator BM 06.022.通过大剂量注射新型重组纤溶酶原激活剂BM 06.022快速逆转犬血栓栓塞性肺动脉高压
J Cardiovasc Pharmacol. 1993 Mar;21(3):455-61. doi: 10.1097/00005344-199303000-00016.
5
Effects of hydralazine and increased cardiac output on recombinant tissue plasminogen activator-induced thrombolysis in canine pulmonary embolism.肼屈嗪及心输出量增加对犬肺栓塞模型中重组组织型纤溶酶原激活剂诱导溶栓的影响
Chest. 1991 Mar;99(3):708-14. doi: 10.1378/chest.99.3.708.
6
Effect of low-molecular-weight heparin on recombinant tissue plasminogen activator-induced thrombolysis in canine pulmonary embolism.低分子量肝素对犬肺栓塞中重组组织型纤溶酶原激活剂诱导溶栓的影响。
Chest. 1991 Aug;100(2):464-9. doi: 10.1378/chest.100.2.464.
7
A randomized trial of a single bolus dosage regimen of recombinant tissue plasminogen activator in patients with acute pulmonary embolism.
Chest. 1990 Dec;98(6):1473-9. doi: 10.1378/chest.98.6.1473.
8
Optimizing coronary thrombolysis with i.v. administration of recombinant tissue plasminogen activator. Single bolus vs double bolus vs front-loading.静脉注射重组组织型纤溶酶原激活剂优化冠状动脉溶栓治疗。单次推注与两次推注与负荷剂量法。
Chest. 1996 Feb;109(2):510-5. doi: 10.1378/chest.109.2.510.
9
Early reversal of right ventricular dysfunction in patients with acute pulmonary embolism after treatment with intravenous tissue plasminogen activator.
J Am Coll Cardiol. 1987 Nov;10(5):971-8. doi: 10.1016/s0735-1097(87)80333-9.
10
Marked systemic hypotension depresses coronary thrombolysis induced by intracoronary administration of recombinant tissue-type plasminogen activator.
J Am Coll Cardiol. 1992 Dec;20(7):1626-33. doi: 10.1016/0735-1097(92)90459-z.

引用本文的文献

1
Advances in thrombolytic therapy.溶栓治疗的进展。
Cardiovasc Drugs Ther. 1992 Apr;6(2):111-24. doi: 10.1007/BF00054557.